159 related articles for article (PubMed ID: 36099437)
21. Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors.
Lanzi C; Arrighetti N; Pasquali S; Cassinelli G
Biochem Pharmacol; 2023 Sep; 215():115727. PubMed ID: 37541451
[TBL] [Abstract][Full Text] [Related]
22. The Achilles Heel of Malignant Rhabdoid Tumors.
Huang J; Luo J
Cancer Res; 2019 Jun; 79(11):2808-2809. PubMed ID: 31160308
[TBL] [Abstract][Full Text] [Related]
23. SMARCB1 protein and mRNA loss is not caused by promoter and histone hypermethylation in epithelioid sarcoma.
Papp G; Changchien YC; Péterfia B; Pecsenka L; Krausz T; Stricker TP; Khoor A; Donner L; Sápi Z
Mod Pathol; 2013 Mar; 26(3):393-403. PubMed ID: 23174932
[TBL] [Abstract][Full Text] [Related]
24. SMARCB1/INI1 genetic inactivation is responsible for tumorigenic properties of epithelioid sarcoma cell line VAESBJ.
Brenca M; Rossi S; Lorenzetto E; Piccinin E; Piccinin S; Rossi FM; Giuliano A; Dei Tos AP; Maestro R; Modena P
Mol Cancer Ther; 2013 Jun; 12(6):1060-72. PubMed ID: 23576573
[TBL] [Abstract][Full Text] [Related]
25. SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.
Kuwahara Y; Wei D; Durand J; Weissman BE
Mol Cancer Res; 2013 Mar; 11(3):251-60. PubMed ID: 23364536
[TBL] [Abstract][Full Text] [Related]
26. SWI/SNF-deficient thoraco-pulmonary neoplasms.
Sesboue C; Le Loarer F
Semin Diagn Pathol; 2021 May; 38(3):183-194. PubMed ID: 33451916
[TBL] [Abstract][Full Text] [Related]
27. SWI/SNF deficient central nervous system neoplasms.
Cai C
Semin Diagn Pathol; 2021 May; 38(3):167-174. PubMed ID: 33762087
[TBL] [Abstract][Full Text] [Related]
28. Prognostic determinants in epithelioid sarcoma.
Gasparini P; Facchinetti F; Boeri M; Lorenzetto E; Livio A; Gronchi A; Ferrari A; Massimino M; Spreafico F; Giangaspero F; Forni M; Maestro R; Alaggio R; Pilotti S; Collini P; Modena P; Sozzi G
Eur J Cancer; 2011 Jan; 47(2):287-95. PubMed ID: 20932739
[TBL] [Abstract][Full Text] [Related]
29. [Pathological and molecular features of malignancies underlined by BAF complexes inactivation].
Le Quang M; Ranchère-Vince D; Le Loarer F
Ann Pathol; 2019 Dec; 39(6):399-413. PubMed ID: 31255411
[TBL] [Abstract][Full Text] [Related]
30. INI1-deficient tumors: diagnostic features and molecular genetics.
Hollmann TJ; Hornick JL
Am J Surg Pathol; 2011 Oct; 35(10):e47-63. PubMed ID: 21934399
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic regulation of SMARCB1 By miR-206, -381 and -671-5p is evident in a variety of SMARCB1 immunonegative soft tissue sarcomas, while miR-765 appears specific for epithelioid sarcoma. A miRNA study of 223 soft tissue sarcomas.
Sápi Z; Papp G; Szendrői M; Pápai Z; Plótár V; Krausz T; Fletcher CD
Genes Chromosomes Cancer; 2016 Oct; 55(10):786-802. PubMed ID: 27223121
[TBL] [Abstract][Full Text] [Related]
32. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors.
Carugo A; Minelli R; Sapio L; Soeung M; Carbone F; Robinson FS; Tepper J; Chen Z; Lovisa S; Svelto M; Amin S; Srinivasan S; Del Poggetto E; Loponte S; Puca F; Dey P; Malouf GG; Su X; Li L; Lopez-Terrada D; Rakheja D; Lazar AJ; Netto GJ; Rao P; Sgambato A; Maitra A; Tripathi DN; Walker CL; Karam JA; Heffernan TP; Viale A; Roberts CWM; Msaouel P; Tannir NM; Draetta GF; Genovese G
Cancer Cell; 2019 Feb; 35(2):204-220.e9. PubMed ID: 30753823
[TBL] [Abstract][Full Text] [Related]
33. Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma.
Hornick JL; Dal Cin P; Fletcher CD
Am J Surg Pathol; 2009 Apr; 33(4):542-50. PubMed ID: 19033866
[TBL] [Abstract][Full Text] [Related]
34. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors.
Wang X; Wang S; Troisi EC; Howard TP; Haswell JR; Wolf BK; Hawk WH; Ramos P; Oberlick EM; Tzvetkov EP; Ross A; Vazquez F; Hahn WC; Park PJ; Roberts CWM
Nat Commun; 2019 Apr; 10(1):1881. PubMed ID: 31015438
[TBL] [Abstract][Full Text] [Related]
35. SWI/SNF Chromatin-remodeling Complex Status in SMARCB1/INI1-preserved Epithelioid Sarcoma.
Kohashi K; Yamamoto H; Yamada Y; Kinoshita I; Taguchi T; Iwamoto Y; Oda Y
Am J Surg Pathol; 2018 Mar; 42(3):312-318. PubMed ID: 29309303
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments.
Ngo C; Postel-Vinay S
Biomedicines; 2022 Mar; 10(3):. PubMed ID: 35327458
[TBL] [Abstract][Full Text] [Related]
37. ARID1A deficient undifferentiated spindle cell and rhabdoid sarcoma of the prostate: report of a unique case with emphasis on diagnostic implications.
Xu W; Dong H; Ru G; Zhao M
Diagn Pathol; 2022 Feb; 17(1):22. PubMed ID: 35125107
[TBL] [Abstract][Full Text] [Related]
38. Gene of the month: SMARCB1.
Kalimuthu SN; Chetty R
J Clin Pathol; 2016 Jun; 69(6):484-9. PubMed ID: 26941181
[TBL] [Abstract][Full Text] [Related]
39. Malignant rhabdoid tumors of the vulva versus epithelioid sarcomas: a clinicopathologic, immunohistochemical, and molecular genetics study.
Espinosa I; D'Angelo E; De Brot L; Prat J
Hum Pathol; 2023 May; 135():1-10. PubMed ID: 36863690
[TBL] [Abstract][Full Text] [Related]
40. Update on SWI/SNF-related gynecologic mesenchymal neoplasms: SMARCA4-deficient uterine sarcoma and SMARCB1-deficient vulvar neoplasms.
Howitt BE; Folpe AL
Genes Chromosomes Cancer; 2021 Mar; 60(3):190-209. PubMed ID: 33252159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
